Home > Insider Trading > Filing (0001140361-21-037655)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1865494	Io Biotech Inc.	IOBT	Pharmaceutical Preparations (2834)	870909276

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1891515	Vanessa Malier	C/O Io Biotech, Inc. Ole Maaloes Veh 3 Copenhagen G7 2200		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-11-09	796,059	$0.00	796,059	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-11-09	267,977	$0.00	267,977	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-11-09	162,500	$14.00	958,559	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2021-11-09	162,500	$14.00	430,477	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2021-11-09	63,350	$0.00	796,059	$0.00
Common Stock	Series C Preferred Stock	Disposition	2021-11-09	21,325	$0.00	267,977	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any.
The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any.